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Abstract 
A sensitive, specific, reproducible and optimized high performance liquid chromatography with fluorescence detec‑
tion (HPLC‑FLD) method for the determination of bergapten in rat plasma was established and applied to the 
pharmacokinetic and bioavailability study in rat after oral and intravenous administration of bergapten. The method 
was also successfully applied to the excretion study of bergapten after an oral administration of bergapten at a dose 
of 15 mg kg−1 to rats. The sample preparation was achieved using liquid–liquid extraction. Isoimperatorin was used as 
the internal standard (IS). The analytes were detected by using fluorescence detection at an excitation and emission 
wavelength of 288 and 478 nm, respectively. Using aqueous formic acid (0.1 %, v/v) and acetonitrile as the mobile 
phase, the chromatographic separation was achieved on a Hedera™ ODS column at a flow rate of 1 mL min−1. The 
lower limit of quantitation (LLOQ) of bergapten was 2 ng mL−1. The HPLC‑FLD method was successfully applied to the 
pharmacokinetic, bioavailability and excretion study of bergapten in rats.
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Background
Bergapten (Fig.  1), is one of coumarins found in many 
herbal medicines. Pharmacological studies showed that 
bergapten had the analgesic, anti-inflammatory, anti-
coagulant and anti-cancer activities [1, 2]. Bergapten has 
also been known to counteract the proliferative effect and 
cause apoptosis of breast cancer cells [3]. Previous studies 
have shown that bergapten reduced the level of circulating 
estrogen and improved oxidative metabolism [4]. Several 
analytical methods for investigating coumarins in biologi-
cal fluids have been previously reported [5, 6]. Many of 
these methods on bergapten focused on the simultane-
ous determination of two or more compounds including 
bergapten using HPLC–UV [7], LC–MS [4, 5] and high-
speed countercurrent chromatography [8]. Currently, an 
LC–MS/MS method was developed to determine ber-
gapten in dog plasma [9]. To the best of our knowledge, 
no article has focused on oral bioavailability and excretion 
study of pure compound of bergapten in rats.
Fluorometric analysis is among the most sensitive and 
selective methods for detecting organic and inorganic 
compounds. Coumarins have been known to be interest-
ing fluorophores, with their fluorescences changing dras-
tically with substituents and their introduced positions 
[10]. In this present study, a simple, selective, sensitive 
and optimised HPLC-FLD method has been developed 
for the quantitative determination of bergapten in rat 
plasma using isoimperatorin as an internal standard (IS). 
This analytical method has been successfully applied to 
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the pharmacokinetics, oral bioavailability and excretion 
studies of bergapten after oral and intravenous adminis-
tration to rats. This is an oral bioavailability and excretion 
study that have been reported on bergapten in rats after a 
search into various journals.
Methods
Chemicals and reagents
Acetonitrile (Fisher technologies Inc., USA) and metha-
nol (Tianjin concord Science Co. Ltd., Tianjin, China) 
were of HPLC grade. Standard reference isoimpera-
torin and bergapten (purity >98 %) were purchased from 
National Institute for the Control of Pharmaceutical and 
Biological Products (Beijing, China). Ethyl acetate and 
formic acid were of analytical grade. Deionized water 
was purified with a Milli-Q Academic ultra-pure water 
system (Millipore, Milford, MA, USA) and used for the 
HPLC mobile phase.
Apparatus and chromatographic conditions
HPLC analysis was performed on an Agilent 1100 
HPLC (Agilent Technologies, USA) equipped with a 
quaternary pump, a degasser, an autosampler, a col-
umn thermostat and a fluorescence detector. An agi-
lent fluorescence detector was coupled to the Agilent 
system. Separation was carried out with a Hedera™ 
ODS column (4.6  ×  250  mm, 5  μm) by gradient elu-
tion at a temperature of 30 °C. Excitation and emission 
of the fluorescence detector was set to 288 and 478 nm, 
respectively. A constant flow rate of 1.0 mL min−1 and 
an injection volume of 30 μL were employed throughout 
the analysis. A mobile phase comprising of aqueous for-
mic acid (0.1 %, v/v) (solvent system A) and acetonitrile 
(solvent system B) was employed with a gradient elution 
of 40–80 % B at 0 to 5 min, 80–85 % B at 5 to 10 min, 
85–90  % B at 10 to 12  min, 90–95  % B at 12–15  min, 
95 % B at 15–20 min. The re-equilibration time of gradi-
ent elution was 8 min.
Preparation of stock solution, calibration standards
In preparing the stock solution, appropriate amount of 
bergapten was weighed and dissolved in methanol to 
achieve a concentration of 1.0  mg  mL−1. The chemical 
structures of bergapten and isoimperatorin are shown 
in Fig. 1. Working solutions of bergapten were then pre-
pared by appropriate dilution with methanol for use. The 
stock solution of internal standard, isoimperatorin was 
also dissolved in methanol and diluted with methanol to 
a final concentration of 1 μg mL−1 and stored at 4 °C until 
analysis.
10 μL aliquots of bergapten working solutions were 
added to 100 μL drug-free rat plasma to obtain bergapten 
calibration standards (2, 4, 8, 20, 40, 100 and 100, 200, 
500, 1000, 2500, 5000  ng  mL−1) in plasma samples for 
two calibration curves.
Sample pretreatment and quality samples
To a 100 μL aliquot of plasma sample, 10 μL internal 
standard solutions were added. Samples were vortex-
mixed for 2 min, extracted with 1000 μL ethyl acetate and 
then centrifuged for 10  min at 14,000  rpm. The super-
natant was transferred into another centrifuge tube and 
evaporated to dryness using nitrogen gas. The dried resi-
due was reconstituted by adding 100 μL methanol. The 
solution was shaken and ultrasonicated for 2 min. It was 
then centrifuged at 14,000  rpm for 10  min. A 30 μL of 
the solution was run with the HPLC and analysis was 
performed.
For the quality control (QC) samples (2, 6, 500 and 
5000 ng mL−1), blank rat plasma was spiked with appro-
priate standard solutions of bergapten to the required 
plasma concentrations, followed by the same sample 
preparation and extraction method described above.
Method validation
Testing for specificity involved comparing the chromato-
grams of six different batches of blank rat plasma samples 
with that of their corresponding spiked plasma. The limit 
of detection (LOD) was defined as the amount of analyte 
that could be detected with a signal to noise ratio of 3. 
The lower limit of quantification (LLOQ), which is the 
lowest concentration in the standard curve at which the 
signal to noise ratio (S/N) was to be larger than 5, with 
relative standard deviation (RSD n = 6) within 20 % and 
accuracy in the range of 80  % to 120 according to the 
guidelines for industry (2001). In determining the lin-
earity of the method, samples were prepared by spiking 
blank rat plasma with standard solutions (prepared in 
methanol) of bergapten to the concentrations: 2, 4, 8, 20, 
40, 100 and 100, 200, 500, 1000, 2500 and 5000 ng mL−1 
Fig. 1 Chemical structures of bergapten and isoimperatorin (IS)
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for the calibration curves. In determining the intra-day 
accuracy and precision, four quality control (QC) sam-
ples (n = 6) were assayed within the same day. This was 
in turn repeated once a day for 3 consecutive days to 
evaluate the inter-day precision along with the standard 
calibration curve. The determination of the extraction 
recoveries was performed by comparing the observed 
peak areas of bergapten in extracted plasma samples with 
those of the bergapten in non-processed plasma sam-
ples at the same theoretical concentrations. The tests for 
stability were investigated for bergapten in autosampler 
for 24  h, after 3 times freeze and thaw cycles and also 
after storing in a freezer at a temperature of −20  °C for 
1 month.
Application to a pharmacokinetic study in rats
Male Sprague–Dawley rats (240–260  g) were fed with 
standard laboratory food and water and kept in an envi-
ronmentally-controlled breeding room for at least 1 week 
before experimentation. The rats were fasted for 12 h and 
allowed free access to water prior to the experiments. The 
rats were randomly divided into 4 groups with eight rats 
in each group to diminish the individual variation. The 
first group was given bergapten intravenously at a dose 
of 5 mg kg−1 while the other three groups were given ber-
gapten orally at doses of 5, 10 and 15 mg kg−1. Disposable 
sterilized syringes were used for intravenous administra-
tion and medical cotton ball was pressured on the wound 
until bloodless after injection. Blood samples (about 250 
μL) were immediately collected in heparinized 1.5  mL 
polythene tubes from the suborbital vein at 0, 0.5, 0.75, 
1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 12, 24 h after oral administra-
tion. For intravenous administration, time intervals were 
set at 0, 0.033, 0.083, 0.17, 0.25, 0.33, 0.5, 0.75, 1, 2, 3, 4, 
6, 8, 12, 24 h for blood sampling. All blood samples were 
immediately centrifuged to separate plasma at 6000 rpm 
for 10 min. The plasma was transferred into clean tubes 
and stored at −20  °C until analysis. Animal welfare and 
experimental procedures were strictly in accordance with 
the guide for the care and use of laboratory animals and 
the related ethical regulations of Tianjin University of 
Traditional Chinese Medicine.
Excretion of bergapten in rat urine, feces and bile
Sixteen male Sprague–Dawley (SD) rats (250  ±  10  g) 
were divided into two groups (group1 were for collecting 
urine and fecal samples in metabolic cages while group 2 
were for collecting bile samples from the bile duct using 
polyethylene tubes). For group 1, the rats were orally 
administrated with bergapten dissolved in 0.5  % CMC-
Na at a dosage of 15  mg  kg−1 and placed in metabolic 
cages enabling collection of urine and fecal samples sepa-
rately. The urine and fecal samples were collected at time 
interval of 0–4, 4–8, 8–12, 12–24, 24–36, 36–48, 48–60, 
and 60–72  h. For Group 2, the rats were anaesthetised 
with chloral hydrate at a dose of 0.3 g kg−1 administered 
intraperitoneally. A polyethene tube was used in cannula 
ting the bile duct ensuring continuous flow of bile. Bile 
samples were then collected at different time intervals 
(0–1, 1–2, 2–3, 3–4, 4–5, 5–6, 6–7, 7–8, 8–9 and 9–10 h). 
After the volumes of urine and bile obtained were meas-
ured, these samples were stored at −20 °C until analysis. 
The preparation of the urine and bile samples were the 
same as the plasma sample preparation described above. 
The fecal samples, on the other hand, after collection 
were dried out in a drying oven at 40  °C. After measur-
ing the weights of the fecal samples, they were crushed 
by a mortar to achieve a uniform powder. 0.1 g of pow-
dered feces was measured and 1 mL methanol was added 
in 1.5  mL polythene tubes, mixed sufficiently for 3  min 
by vortexing and extracted ultrasonically for 30  min. 
Supernatant were transferred into vials for analysis using 
HPLC-FLD.
Data analysis
The DAS software (Drug and Statistics 1.0, Medical Col-
lege of Wannan, China), a computer program was used 
in calculating the pharmacokinetic parameters after 
administering bergapten both intravenously and orally at 
dose of 5 and 5, 10, 15 mg kg−1, respectively. To choose 
the optimum compartment model for fitting the plasma 
concentration–time curve, the minimum Akaike’s infor-
mation criterion (AIC) estimation was tested by calculat-
ing the lowest AIC value. The compartment model with 
minimum AIC is regarded as the best representation of 
the plasma concentration–time course data [10]. The 
bioavailability was calculated as follows: F  =  (AUCoral/
AUCintravenous) × 100 %. Both AUC oral and AUC intrave-
nous were estimated by one-compartment model.
Results and discussion
Optimization of the fluorescence spectra
The excitation and emission wavelengths of bergapten 
were optimized to obtain a suitable detection wavelength 
with an increased signal to noise (S/N). After several 
examinations, an excitation wavelength of 288  nm and 
emission wavelength of 478  nm was the most suitable 




Figure  2 shows the representative chromatograms of 
blank plasma, blank plasma samples spiked with ber-
gapten and plasma sample obtained from a rat follow-
ing an injection of bergapten. The retention time of 
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bergapten was 7.3 min and IS was 10.2 min. As described 
above, good resolution was achieved between analyte and 
IS and no substance from several different sources of rat 
plasma was observed interfering with the separation and 
quantitation of bergapten. In the real pharmacokinetic 
study samples, no metabolite or endogenous substance 
interfered with the determination of the analytes.
Calibration curve and lower limits of quantification
The model of calibration for the two calibration curves 
was selected based on the analysis of the data by lin-
ear regression and with weighting factor (1/x). The 
peak area ratio of bergapten to IS in rat plasma was lin-
ear in relation to the concentration of the analyte for 
the ranges, 2–100  ng  mL−1 and 100–5000  ng  mL−1. 
The regression equation for calibration one was 
Y  =  0.006581X  −  0.00793 (correlation coefficient, 
r  =  0.9990), and that for the second calibration was 
Y  =  0.007403X  +  0.050226 (correlation coefficient, 
r = 0.9992) over the range 100-5000 ng mL−1. The LOD 
for bergapten was found to be 1 ng mL−1 (S/N ≥ 3) and 
LLOQ was 2 ng mL−1(S/N ≥ 5).
Accuracy and precision
Both intra-day and inter-day accuracy and precision val-
ues of the method are shown in Table  1. The intra-day 
coefficient of variation (RSD  %) for bergapten ranged 
from 4.29 to 11.6 % and the accuracy from 97.4 to 109 %. 
RSD of the inter-day for the analyte was from 7.13 to 
13.6 % and the accuracy from 93.7 to 107 %. The results 
indicated that the assay was reproducible, accurate and 
reliable.
Extraction efficiency
The recovery of bergapten was higher than 80  % at all 
the four concentrations studied (Table 2) and the extrac-
tion efficiency did not show obvious dependent relation 
with concentration. It was concluded that liquid–liquid 
extraction with ethyl acetate proved to be efficient in 
extracting bergapten from the plasma sample.
Stability
The results from the stability tests are shown in Table 3. 
It was found that bergapten was stable in rat plasma after 
three freeze–thaw cycles. Bergapten was also stable in 
the auto-sampler for a period of 24  h. The reduction of 
bergapten content in the rat plasma observed under any 
of those conditions was not significant. The above results 
demonstrated that bergapten could be determined in rat 
plasma by the developed HPLC method.
Pharmacokinetic studies
Pharmacokinetics of bergapten in rats after intravenous 
administration
The pharmacokinetics of bergapten in rat plasma after 
administering bergapten both intravenously and orally 
was successfully studied using the developed method. 
After intravenous administration of bergapten at dose of 
5 mg kg−1 to rats, the mean plasma concentration–time 
profile of bergapten is shown in Fig. 3. Some important 
pharmacokinetic parameters have been listed in Table 4. 
The distribution of bergapten into the tissues was slow 
and this is indicated by the long distribution half-life, 
T1/2α of 2  h. The plasma concentration of bergapten 
decreased gradually within the first 4 h after interavenous 
administration, and then slowly decreased to the LLOQ 
during the next 8 h. The average volume of distribution 
is 0.0027 ± 0.0006 L Kg−1. The mean area for the plasma 
concentration–time curve from time zero to the last 
measurable plasma concentration point (AUC0–tn) was 
4391 ± 1363 ng (mL h)−1 and the mean area under the 
plasma concentration–time curve from time zero to time 
infinity (AUC0–∞) was 4474 ± 1322 ng (mL h)−1.
Pharmacokinetics of bergapten in rats after oral 
administration
After administering bergapten orally at doses of 5, 10 and 
15 mg kg−1, the mean plasma concentration–time curves 
are illustrated in Fig.  3. The major pharmacokinetic 
Fig. 2 Representative chromatogram of a blank rat plasma, b blank 
rat plasma spiked with standard compounds, and c real sample after 
oral administration 5 mg kg−1of bergapten. 1 bergapten, 2 isoimpera‑
torin
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parameters of bergapten are presented in Table 5. After 
oral administration, the absorption of bergapten from 
the rat gastrointestinal tract was discovered to be rapid. 
It was detected in the plasma after the first blood was 
sampled at a time of 2 min and Tmax was reached slightly 
rapid for all three oral doses studied. The plasma concen-
tration then decreased to the LLOQ by 24 h. It was also 
observed that the Cmax and AUC after administering ber-
gapten at doses 10 and 15 mg kg−1 were similar. It could 
be inferred here that this concentration was the allowable 
amount of bergapten that can be absorbed by the rats. 
According to the pharmacokinetic calculations by DAS 
1.0 software, which is the authoritative software for the 
pharmacokinetic calculations, a one-compartment model 
of in  vivo metabolism best fit the data on bergapten in 
rats after oral administration.
The mean area under curve AUC(0–tn) from time 0 to 
24  h were 3517 ±  1299, 8255 ±  3536, 9197 ±  5790  ng 
(L  h)−1 and the mean area under the curve from time 
zero to time infinity AUC(0–∞) were 3537  ±  1302, 
8266  ±  3534, 9306  ±  5782  ng (L  h)−1 for 5, 10 and 
15 mg kg−1 doses, respectively. On the other hand, appar-
ent volume of distribution (V) value was 0.02 L kg−1 for 
the oral group, suggesting that this compound could not 
distribute extensively into organs and tissues. The distri-
bution half-life is 9 h and the MRT is 4 h.
Bioavailability of bergaten in rats after administration
The absolute oral bioavailability (F) were 80.1  ±  29.6  %, 
94.0 ± 40.3 % and 69.5 ± 44.2 % for low, medium and high 
concentrations using the formula F = (AUCoral/AUCintravenous)  
×  100 %, based on the AUC(0–∞) obtained after intrave-
nous and oral administration. The AUC of the medium 
and high concentration were similar, it could be inferred 
that the absorption of bergapten reached its peak within 
the range of 10 to 15 mg kg−1. It was demonstrated that 
bergapten might have a good absorption from the gas-
trointestinal tract in rat. It was also concluded that oral 
administration of bergapten may be the better route if it 
was developed the new drugs used in clinic.













2 97.4 8.92 93.7 7.13
6 103 11.6 99.4 13.1
500 108 6.34 107 9.97
5000 109 4.29 106 13.6
Table 2 Recoveries of bergapten (n = 6)
Concentration (ng mL−1) Recovery





Table 3 Stability of bergapten (n = 6)
Concentration (ng mL−1) Freeze thaw cycles Autosampler for 24 h −20 °C for 1 month
Accuracy (%) RSD (%) Accuracy (%) RSD (%) Accuracy (%) RSD (%)
2 89.5 11.9 107 8.69 97.6 7.33
6 101 13.1 110 7.49 96.9 7.71
500 113 5.65 102 4.31 90.5 5.99
5000 92 10.9 91.7 4.85 99.4 9.31





























Fig. 3 The mean plasma concentration–time profiles of bergapten 
after oral (a) and intravenous (b) administration (n = 8, mean ± SD)
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Excretion study of bergapten in rat urine, feces and bile
The cumulative excretion of bergapten in urine, feces 
and bile were determined as shown in Fig.  4. After an 
oral administration of bergapten at a dose of 15 mg kg−1 
to the rats, bergapten could be detected in rat urine 
until 72 h. Bergapten increased rapidly in urine during 
a time period of 4–8 h. After 8 h however, there was a 
gradual increase of bergapten in urine. Bergapten exhib-
ited an increased rise in fecal sample up until a period 
of 36 h, after which the detection of bergapten was sta-
ble with minimal increase or decrease until 72  h. The 
rise was rapid especially in the period of 4–8 h. There-
fore, the time cumulative excretion percentage of ber-
gapten in feces stabilized after 36 h. Owing to the rats’ 
physical conditions, bile samples were only collected 
for a period of 10  h. After a more gradual increase in 
bile for a period of 8 h, bergapten stabilized. As shown 
in Fig. 4, the time cumulative amounts of bergapten in 
feces were 27.99  ±  10.08  % of the total dose, demon-
strating that bergapten was mainly excreted in the feces. 
Even though the time cumulative amount of bergapten 




The development of sensitive and specific assay of a drug 
is crucial to the study of drug pharmacokinetics. The 
HPLC-FLD was first developed to monitor the concen-
tration of bergapten in solution to determine its suit-
ability and sensitivity. The method was further optimized 
for the determination of bergapten in the rat plasma 
and has been validated to be sensitive to investigate the 
pharmacokinetics of bergapten in rats. Bergapten is 
an important furocoumarin because of its presence in 
many TCMs and the various therapeutic effects it pos-
sesses. Bergapten was rapidly absorbed by rats with the 
maximum plasma concentration achieved within 3  h 
after dosing (5 mg kg−1) as seen in Table 1. The kinetic 
properties were fit to the one-compartment model after 
rats were given i.v. administration. The absorption T1/2 
after oral administration was 30 s, which shows that ber-
gapten was also rapidly absorbed. The long distribution 
half-life could explain the reason for high bioavailability 
in rats after oral administration (T1/2α (h) = 9.35 ± 3.06). 
The oral absolute bioavailability were 80.1  ±  29.6  %, 
94.0 ±  40.3  % and 69.5 ±  44.2  % for low, medium and 
high concentration of bergapten, which showed that ber-
gapten was provided with a higher degree of absorption 
from the gastrointestinal tract.
Method comparison with existing reports
A pharmacokinetic study of bergapten was performed 
in dog plasma using an LC–MS/MS method. Tmax and 
AUC(0–∞) were 4.2  h and 3219.2  ±  211.4  ng (mL  h)−1 
respectively which were comparable to that obtained 
from our experiment, giving a Tmax and AUC(0–∞) 
of 3–4.5  h and 3537  ±  1302  ng (mL  h)−1. The LLOQ 
as obtained from the LC–MS/MS experiment was 
0.5  ng  mL−1 which differs from this study which was 
2 ng mL−1 [8]. Our experiment differs from the LC–MS/
Table 4 Pharmacokinetic parameters of  bergapten 





−1) 2080 ± 484
AUC(0–tn) (ng mL
−1 h−1) 4391 ± 1363
AUC(0–∞) (ng mL
−1 h−1) 4474 ± 1323
V/F (L) 0.0027 ± 0.0006
T1/2α (h) 1.74 ± 0.21
MRT(0–tn) (h) 1.80 ± 0.10
MRT(0–∞) (h) 4.05 ± 3.81
Table 5 Pharmacokinetic parameters of bergapten after oral administration of 5, 10, 15 mg kg−1 (n = 8, mean ± SD)
Parameters Low (5 mg kg−1) Medium (10 mg kg−1) High (15 mg kg−1)
Tmax (h) 3.20 ± 0.45 3.88 ± 0.99 4.56 ± 1.40
Cmax (ng mL
−1) 859.4 ± 253.6 1397 ± 573 1307 ± 617
AUC (0–tn) (ng mL
−1 h−1) 3517 ± 1299 8255 ± 3536 9197 ± 5790
AUC(0–∞) (ng mL
−1 h−1) 3537 ± 1302 8266 ± 3534 9306 ± 5782
V/F (L) 0.0107 ± 0.0044 0.0115 ± 0.0139 0.0124 ± 0.0138
T1/2α (h) 9.35 ± 3.07 12.88 ± 12.21 14.35 ± 15.75
MRT(0–tn) (h) 3.72 ± 0.53 4.83 ± 0.47 5.57 ± 1.15
MRT(0–∞) (h) 3.91 ± 0.51 4.87 ± 0.47 6.65 ± 2.27
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MS experiments done on bergapten in that we deter-
mined the oral bioavailability and excretion of bergapten 
in rats. HPLC-FLD offers a cheaper analytical tool option 
compared to the higher cost of LC–MS/MS and HPLC-
FLD requires less technical know-how.
Conclusion
In this study, a sensitive, specific, reproducible and opti-
mized HPLC-FLD method for the determination of ber-
gapten in rat plasma was established and applied to the 
pharmacokinetic, bioavailability and excretion studies 
in rat after administering bergapten orally and intrave-
nously to the rats. The method was thoroughly validated 
over two ranges of concentration of 2–100 ng mL−1 and 
100–5000  ng  mL−1 (r  >  0.999) which produced a good 
intra-day and inter-day accuracy and precision. The 
sample preparation technique used was simple. The 
pharmacokinetics of bergapten follows a one compart-
ment model and was well absorbed after oral adminis-
tration. Base on the high bioavailability of bergapten 
after oral administration in rat, it was suggested that the 
better route of bergapten in clinic was oral administra-
tion. Cumulative excretion of bergapten in urine, feces 
and bile reached 0.032 ± 0.019 %, 27.99 ± 10.08 % and 
0.015  ±  0.006  % of the total dosage, respectively. The 
excretion of bergapten was mainly through fecal route. 
For the first time, the oral bioavailability and excre-
tion study of bergapten were reported in rats using 
HPLC-FLD method, which will provide more useful 
information on bergapten in in  vivo pharmacological 
investigation and the new drug research. Pharmacoki-
netic and bioavailability study on bergapten can also be 
applied in evaluating the clinical efficiency of bergapten 
as used in clinic.
Authors’ contributions
JC and YC conceived of and designed the experiments. XY, JTA and JL and MA 
performed the experiments and analyzed the data. YC, JL, HJ and JH collected 
and authenticated the herbs and analyzed the data. XY, YC and John TA wrote 
the paper. All authors read and approved the final manuscript.
Author details
1 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University 
of Traditional Chinese Medicine, Tianjin 300193, China. 2 Department of Sur‑
gery, University of Michigan, Ann Arbor, MI 48109, USA. 3 College of Material 
Chemistry and Chemical Engineering, Hangzhou Normal University, Hang‑
zhou 310036, China. 
Acknowledgements
This research was supported National Natural Science Foundation of China 
(81503213 and 81374050), National Science and Technology Support Program 
Projects (2014BA105B01), Stated Key Development Program for Basic Research 
of China (No. 973: 2014CB542902), PCSIRT (IRT‑14R41) and State the Science 
& Technology Commission of MOST of China (2014ZX09304307‑001‑005 and 
2014ZX09201022‑004).
Competing interests
The authors declare that they have no competing interests.
Fig. 4 Time cumulative excretion percentage of bergapten (a1) in urine, (b1) in feces and (c1) in bile; cumulative excretion percentage at different 
time of bergapten (a2) in urine, (b2) in feces and (c2) in bile
Page 8 of 8Yu et al. Chemistry Central Journal  (2016) 10:62 
Received: 22 July 2016   Accepted: 7 October 2016
References
 1. Hu C, Xu G (2014) Metabolomics and traditional Chinese medicine. TrAC 
Trends Anal Chem 61:207–214
 2. Okuyama E, Nishimura S, Ohmori S, Ozaki Y, Satake M, Yamazaki M (1993) 
Analgesic component of Notopterygium incisum Ting. Chem Pharm Bull 
41:926–929
 3. Qian GS, Wang Q, Leung KS, Qin Y, Zhao Z, Jiang ZH (2007) Quality assess‑
ment of Rhizoma et Radix Notopterygii by HPTLC and HPLC fingerprint‑
ing and HPLC quantitative analysis. J Pharm Biomed Anal 44:812–817
 4. Li J, Ma B, Zhang Q, Yang X, Sun J, Tang B, Cui G, Yao D, Liu L, Gu G, Zhu 
J, Wei P, Ouyang P (2014) Simultaneous determination of osthole, ber‑
gapten and isopimpinellin in rat plasma and tissues by liquid chromatog‑
raphy‑tandem mass spectrometry. J Chromatogr 970:77–85
 5. Zhang YB, Yang XW (2010) A simple RP‑HPLC method for quantification 
of columbianadin in rat plasma and its application to pharmacokinetic 
study. Biomed Chromatogr 24:433–437
 6. Macmaster AP, Owen N, Brussaux S, Brevard H, Hiserodt R, Leijs H, Bast 
N, Weber B, Loesing G, Sherlock A, Schippa C, Vey M, Frerot E, Tissot E, 
Chaintreau A (2012) Quantification of selected furocoumarins by high‑
performance liquid chromatography and UV‑detection: capabilities and 
limits. J Chromatogr A 1257:34–40
 7. Lia HB, Chen F (1061) Preparative isolation and purification of bergapten 
and imperatorin from the medicinal plant Cnidium monnieri using 
high‑speed counter‑current chromatography by stepwise increasing the 
flow‑rate of the mobile phase. J Chromatogr A 2004:51–54
 8. Gao Y, Liu YZ, Zhang XM, Zhou Y, Zhang X, Dong CY (2013) Pharmacoki‑
netic studies of bergapten in dog plasma by using a LC‑MS/MS method 
studies. Drug Res 63:338–341
 9. Guidance for Industry (2001) Bioanalytical Method Validation U.S. Depart‑
ment of Health and Human Services, Food and Drug Administration 
Centre for Drug Evaluation and Research (CDER), Centre for Veterinary 
Medicine (CVM)
 10. Lv G, Lou Z, Chen S, Gu H, Shan L (2011) Pharmacokinetics and tissue 
distribution of 2,3,5,4′‑tetrahydroxystilbene‑2‑O‑β‑d‑glucoside from 
traditional Chinese medicine Polygonum multiflorum following oral 
administration to rats. J Ethnopharmacol 137:449–456
